Tandem Diabetes Care Enters Material Definitive Agreement

TL;DR

Tandem Diabetes Care signed a big deal on 5/22. Details TBD.

AI Summary

On May 22, 2024, Tandem Diabetes Care, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such as the counterparty or the financial terms, but it is categorized under 'Entry into a Material Definitive Agreement'.

Why It Matters

This filing indicates a significant new contract or partnership for Tandem Diabetes Care, which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the agreement.

Key Players & Entities

• Tandem Diabetes Care, Inc. (company) — Registrant
• May 22, 2024 (date) — Date of earliest event reported
• 001-36189 (other) — Commission File Number
• 20-4327508 (other) — I.R.S. Employer Identification No.
• 12400 High Bluff Drive (address) — Principal executive offices
• San Diego (location) — City of principal executive offices
• California (location) — State of principal executive offices
• 92130 (zip_code) — Zip code of principal executive offices
• ( 858 ) 366-6900 (phone_number) — Registrant's telephone number

FAQ

From the Filing

0001438133-24-000158.txt : 20240618 0001438133-24-000158.hdr.sgml : 20240618 20240618163122 ACCESSION NUMBER: 0001438133-24-000158 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240522 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20240618 DATE AS OF CHANGE: 20240618 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC CENTRAL INDEX KEY: 0001438133 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 204327508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36189 FILM NUMBER: 241052305 BUSINESS ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 BUSINESS PHONE: 858-366-6900 MAIL ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 8-K 1 tndm-20240522.htm 8-K tndm-20240522 0001438133 FALSE 0001438133 2024-05-22 2024-05-22   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 8-K ____________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 ____________________________ Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) ____________________________ Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer  Identification No.) 12400 High Bluff Drive 92130 San Diego California (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 858 )  366-6900 N/A (Former name or former address, if changed since last report) ____________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share TNDM NASDAQ Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ____________________________ Item 1.01 Entry into a Material Definitive Agreement. On May 22, 2024, Tandem Diabetes Care, Inc., a Delaware corporation (the “Company”) and Dexcom, Inc., a Delaware corporation (“Dexcom”) entered into an Amended and Restated Development Agreement to the Original Development Agreement, dated as of November 20, 2020, between the Company and Dexcom, under which the integration of the Company’s insulin pumps with Dexcom’s Continuous Glucose Monitoring (“CGM”) devices are addressed. The Amended and Restated Development Agreement incorporates the inte